Homepage Top Section1

The collaboration will combine the immuno-oncology expertise and pipeline of Kyn Therapeutics with the capabilities of Celgene in development and commercialization of drugs in areas of high unmet

Through the investment, Schott plans to expand its primary business of glass tubing, used as the starting material for pharmaceutical packaging, and also pharmaceutical packaging made of glass and

The designation to SLN124 was granted by the Committee for Orphan Medicinal Products (COMP), a committee of the European Medicines Agency (EMA). COMP after reviewing an application filed

The pharma giant filed two new drug applications (NDAs) with the regulator covering the two forms of tafamidis – meglumine salt and free acid. The company said that

Sylvant secured approval in over 40 countries to treat idiopathic multicentric Castleman’s disease (iMCD), which is a subtype of Castleman disease or giant lymph node hyperplasia, lymphoid hamartoma,

Crizanlizumab (SEG101) is a humanized anti-P-selectin monoclonal antibody being studied to restrict VOCs in SCD. The status has been provided based on positive data from the phase II

Catalent will use the investment to enhance drug substance manufacturing capacity and drug product fill/finish capacity at its biologics manufacturing sites in Madison of Wisconsin and Bloomington of

As per the agreement, US-based Gilead will buy worldwide rights, with the exception of South Korea, to develop and commercialize novel small molecules against two undisclosed targets. In

Alopecia areata is a chronic autoimmune skin disease, which makes hair loss on the scalp, face and body.  At present, there are no approved therapies for this autoimmune